Results 221 to 230 of about 231,777 (344)
Role of ERβ in Triple-Negative Breast Cancer Associated with p53 and Androgen Receptor. [PDF]
Ito K +9 more
europepmc +1 more source
Abstract Background Due to consequences of energy‐related oligo‐/amenorrhea (Oligo/Amen) among exercising females, recovery of menses (ROM) is a priority. ROM is inconsistently defined and rarely reported with reproductive hormone (estrogen, progesterone) data, making it difficult to know when females achieve adequate recovery. Objective The purpose of
Rebecca J. Mallinson +4 more
wiley +1 more source
Clinical significance of YAP and androgen receptor expression in osteosarcoma: Evidence from a retrospective cohort study. [PDF]
Wang J, Xiang P, Zou C, Wang J.
europepmc +1 more source
An elderly male patient with extramammary Paget disease of the scrotum and multiple metastases was treated with fractionated FLASH‐RT (40 Gy in 5 fractions) in the scrotal lesion. Abstract Objective Ultrahigh‐dose‐rate radiotherapy (FLASH‐RT) has been shown to reduce radiation‐induced normal tissue injury in preclinical studies.
Hui Luo +14 more
wiley +1 more source
Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers. [PDF]
Kim TH +5 more
europepmc +1 more source
ABSTRACT Background The dog is the only large mammal, other than humans, that commonly develops spontaneous prostate cancer (PCa) and is, therefore, considered a valuable model for comparative studies. Estrogens are critical for normal prostate development and contribute to prostatic carcinogenesis in men.
Jennifer Lothion‐Roy +9 more
wiley +1 more source
Targeting the mutant androgen receptor with PROTACs in spinal and bulbar muscular atrophy. [PDF]
Lee C, Lim J.
europepmc +1 more source
DETECTION OF ANDROGEN RECEPTOR IN HUMAN PROSTATIC ADENOMA BY THE AUTORADIOGRAPHY
Takayoshi Demura +3 more
openalex +2 more sources
ABSTRACT Introduction In real‐world practice in Japan, standard treatment for metastatic hormone‐naïve prostate cancer (mHNPC) is androgen deprivation therapy (ADT), administered as monotherapy, combined androgen blockade (CAB), ADT plus androgen receptor pathway inhibitors (ARPIs), or ADT plus docetaxel.
Atsushi Mizokami +14 more
wiley +1 more source

